«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2024年05期

页码:

719-724

栏目:

论著

出版日期:

2024-10-25

文章信息/Info

Title:

Expression characteristics and prediction analysis of platinum-resistant mi RNA in non-small cell lung cancer

作者:

杨 慧¹; 郭丽娟¹; 冯晓丹¹; 李 静¹; 黄成谋²; 蔡兴锐²; 覃英娇³; 王远礼³

570100 海口,海南医学院第一附属医院放疗科¹
570100 海口,海南医学院第一附属医院肿瘤内科²
570100 海口,海南医学院第一附属医院呼吸内科³

Author(s):

Yang Hui¹;  Guo Lijuan¹;  Feng Xiaodan¹;  LI Jing¹;  Huang Chengmo²;  Cai Xingrui²;  Qin Yingjiao³;  Wang Yuanli³.

¹Department of Radiotherapy, The First Affiliated Hospital of Hainan Medical College, Haikou 570100, China; ²Department of Oncology, The First Affiliated Hospital of Hainan Medical College, Haikou 570100, China; ³Department of Respiratory Medicine, The First Affiliated Hospital of Hainan Medical College, Haikou 570100, ChinA

关键词:

非小细胞肺癌;  核糖核酸;  铂类化疗药物;  耐药性;  表达特征

Keywords:

Non-small cell lung cancer;  Ribonucleic acid;  Platinum-based chemotherapy drugs;  Drug resistance;  Expression feature

分类号:

R734.2

DOI:

10.3877/cma.j.issn.1674-6902.2024.05.009

摘要:

目的 分析非小细胞肺癌(non-small cell lung cancer, NSCLC)微小RNA(micro RNA, miRNA)表达特征,预测铂类药物耐药性。 方法 选择2021年9月至2023年4月我院收治的105例NSCLC患者为对象,铂类药物治疗敏感66例为对照组,耐药39例为观察组。采用聚合酶链式反应(polymerase chain reaction, PCR)检测miRNA表达水平。采用多因素Logistic回归分析NSCLC铂类药物耐药的影响因素,通过受试者工作特征曲线(receiver operating characteristic curve, ROC)分析miRNA表达特征预测NSCLC铂类药物耐药性。 结果 观察组miRNA-125b(0.92±0.21)、miRNA-106a(0.87±0.22)、miRNA-181a(0.89±0.13)、miRNA-196a(1.01±0.31)表达水平高于对照组miRNA-125b(1.75±0.35)、miRNA-106a(2.45±0.47)、miRNA-181a(1.04±0.21)、miRNA-196a(2.48±0.55),观察组miRNA-148b(1.78±0.47)低于对照组(0.97±0.16)(P<0.05); 多因素Logistic回归分析显示,miRNA-125b(OR=1.642)、miRNA-106a(OR=2.052)、miRNA-181a(OR=2.092)、miRNA-196a(OR=1.508)及miRNA-148b(OR=0.385)表达水平是NSCLC铂类药物耐药情况的影响因素(P<0.05); ROC曲线显示,miRNA-125b、miRNA-106a、miRNA-181a、miRNA-196a及miRNA-148b表达水平预测NSCLC铂类药物耐药的AUC分别为0.795、0.895、0.733、0.878、0.888,miRNA-106a有预测价值,最佳诊断界值为1.220时,预测NSCLC铂类药物耐药的敏感性76.62%,特异性为96.97%。 结论 miRNA表达特征可预测NSCLC铂类药物耐药情况, miRNA-125b、miRNA-106a、miRNA-181a、miRNA-196a表达水平高及miRNA-148b表达水平低的NSCLC患者易发生铂类药物耐药。

Abstract:

Objective To analyze the expression characteristics of micro RNA(miRNA)in non-small cell lung cancer(NSCLC)and predict the resistance of platinum drugs. Methods All of 105 patients with NSCLC admitted to our hospital from September 2021 to April 2023 were selected as subjects, 66 patients with platinum therapy sensitivity were selected as control group, and 39 patients with drug resistance were selected as observation group. miRNA expression was detected by polymerase chain reaction(PCR). Multivariate Logistic regression was used to analyze the influencing factors of platinum drug resistance in NSCLC, and the expression characteristics of miRNA were analyzed by receiver operating characteristic curve(ROC)to predict platinum drug resistance in NSCLC. Results The expression levels of miRNA-125b(0.92±0.21), miRNA-106a(0.87±0.22), miRNA-181a(0.89±0.13)and miRNA-196a(1.01±0.31)in observation group were higher than those in control group(1.75±0.35). miRNA-106a(2.45±0.47), miRNA-181a(1.04±0.21), miRNA-196a(2.48±0.55), miRNA-148b(1.78±0.47)in observation group was lower than that in control group(0.97±0.16)(P<0.05). Multivariate Logistic regression analysis showed that the expression levels of miRNA-125b(OR=1.642), miRNA-106a(OR=2.052), miRNA-181a(OR=2.092), miRNA-196a(OR=1.508)and miRNA-148b(OR=0.385)were platinum drug resistant in NSCLC influencing factors of the situation(P<0.05); ROC curve showed that the expression levels of miRNA-125b, miRNA-106a, miRNA-181a, miRNA-196a and miRNA-148b predicted the AUC of platinum drug resistance in NSCLC were 0.795, 0.895, 0.733, 0.878 and 0.888, respectively. The predictive value of miRNA-106a was high. When the optimal diagnostic threshold was 1.220, the sensitivity and specificity of mirNA-106A for predicting platinum drug resistance in NSCLC were 76.62% and 96.97%. Conclusion The expression characteristics of miRNA can predict platinum drug resistance in NSCLC. NSCLC patients with high expression levels of mirNA-125b, mirNA-106A, mirNA-181A, mirNA-196a and low expression levels of mirNA-148b are prone to platinum drug resistance.

参考文献/References:

1 Cheng Y, Mo F, Li Q, et al. Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin[J]. Mol Cancer, 2021, 20(1): 62.
2 吴国明, 钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
3 Zhou H, Zhou L, Guan Q, et al. Skp2-mediated MLKL degradation confers cisplatin-resistant in non-small cell lung cancer cells[J]. Commun Biol, 2023, 6(1): 805.
4 Larrue R, Fellah S, Boukrout N, et al. miR-92a-3p regulates cisplatin-induced cancer cell death[J]. Cell Death Dis, 2023, 14(9): 603.
5 Ma P, Han W, Meng C, et al. LINC02389/miR-7-5p regulated cisplatin resistance of non-small-cell lung cancer via promoting oxidative stress[J]. Anal Cell Pathol(Amst), 2022, 2022: 6100176.
6 Wu Y, Wang D, Lou Y, et al. Regulatory mechanism of α-hederin upon cisplatin sensibility in NSCLC at safe dose by destroying GSS/GSH/GPX2 axis-mediated glutathione oxidation-reduction system[J]. Biomed Pharmacother, 2022, 150: 112927.
7 Pan G, Liu Y, Shang L, et al. EMT-associated microRNAs and their roles in cancer stemness and drug resistance[J]. Cancer Commun(Lond), 2021, 41(3): 199-217.
8 Kryczka J, Kryczka J, Czarnecka-chrebelska KH, et al. Molecular mechanisms of chemoresistance induced by cisplatin in NSCLC cancer therapy[J]. Int J Mol Sci, 2021, 22(16): 8885.
9 中华医学会, 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2018版)[J]. 中华肿瘤杂志, 2018, 40(12): 935-964.
10 Ruffini E, Fang W, Guerrera F, et al. The international association for the study of lung cancer thymic tumors staging project: The impact of the eighth edition of the union for international cancer control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors[J]. J Thorac Oncol, 2020, 15(3): 436-447.
11 朱 立, 戴五敏, 卢德赵. 非小细胞肺癌顺铂耐药相关基因生物信息学研究[J]. 中国肿瘤生物治疗杂志, 2020, 27(11): 1278-1283.
12 Ashrafizadeh M, Zarrabi A, Hushmandi K, et al. Lung cancer cells and their sensitivity/resistance to cisplatin chemotherapy: Role of microRNAs and upstream mediators[J]. Cell Signal, 2021, 78: 109871.
13 Wang S, Li M Y, Liu Y, et al. The role of microRNA in cisplatin resistance or sensitivity[J]. Expert Opin Ther Targets, 2020, 24(9): 885-897.
14 孙瑾喆, 陈 骏. DNA甲基化在肺癌顺铂耐药中的研究进展[J]. 中国肺癌杂志, 2023, 26(1): 52-58.
15 Massa C, Seliger B. Combination of multiple omics techniques for a personalized therapy or treatment selection[J]. Front Immunol, 2023, 14: 1258013.
16 Konoshenko M, Lansukhay Y, Krasilnikov S, et al. MicroRNAs as predictors of lung-cancer resistance and sensitivity to cisplatin[J]. Int J Mol Sci, 2022, 23(14): 7594.
17 Gohlke L, Alahdab A, Oberhofer A, et al. Loss of key EMT-regulating miRNAs highlight the role of ZEB1 in EGFR tyrosine kinase inhibitor-resistant NSCLC[J]. Int J Mol Sci, 2023, 24(19): 14742.
18 Li X, He S, MA B. Autophagy and autophagy-related proteins in cancer[J]. Mol Cancer, 2020, 19(1): 12.
19 Al-Shumary DS, Al-Shammari AM, Rasheed MN. Increased expression of the ABCA1 and ABCA3 transporter genes is associated with cisplatin resistance in breast cancer cells[J]. Asian Pac J Cancer Prev, 2023, 24(11): 3969-3977.
20 Safari F, Rayat Azad N, Alizadeh Ezdiny A, et al. Antitumor activities of green tea by up-regulation of miR-181a expression in LNCaP cells using 3D cell culture model[J]. Avicenna J Med Biotechnol, 2022, 14(1): 89-94.
21 Bahrami A, Ferns GA. Diagnostic, prognostic, and therapeutic value of miR-148b in human cancers[J]. Curr Mol Med, 2022, 22(10): 860-869.
22 Jiang Z, Zhang J, Chen F, et al. MiR-148b suppressed non-small cell lung cancer progression via inhibiting ALCAM through the NF-κB signaling pathway[J]. Thorac Cancer, 2020, 11(2): 415-425.
23 Yuan X, Jing Y, Guang M, et al. GAS5 alleviates cisplatin drug resistance in oral squamous cell carcinoma by sponging miR-196a[J]. J Int Med Res, 2022, 50(10): 3000605221132456.
24 Sadeghi MS, Lotfi M, Soltani N, et al. Recent advances on high-efficiency of microRNAs in different types of lung cancer: a comprehensive review[J]. Cancer Cell Int, 2023, 23(1): 284.
25 Daneshpour M, Ghadimi-daresajini A. Overview of miR-106a regulatory roles: from cancer to aging[J]. Bioengineering(Basel), 2023,10(8): 892.
26 Pan YJ, Zhuang Y, Zheng JN, et al. MiR-106a: Promising biomarker for cancer[J]. Bioorg Med Chem Lett, 2016, 26(22): 5373-5377.
27 Ahmed Mohmmed E, Shousha WG, El-Saiid AS, et al. A clinical evaluation of circulating mir-106a and raf-1 as breast cancer diagnostic and prognostic markers[J]. Asian Pac J Cancer Prev, 2021, 22(11): 3513-3520.
28 Li J, Hu C, Chao H, et al. Exosomal transfer of miR-106a-5p contributes to cisplatin resistance and tumorigenesis in nasopharyngeal carcinoma[J]. J Cell Mol Med, 2021, 25(19): 9183-9198.
29 He Y, Wang G, Zhang L, et al. Biological effects and clinical characteristics of microRNA-106a in human colorectal cancer[J]. Oncol Lett, 2017, 14(1): 830-836.
30 Khuu C, Utheim TP, Sehic A. The three paralogous microrna clusters in development and disease, miR-17-92, miR-106a-363, and miR-106b-25[J]. Scientifica(Cairo), 2016, 2016: 1379643.

备注/Memo

备注/Memo:

通信作者: 李 静, Email: 737802022@qq.com

常用功能

更新日期/Last Update: 2024-10-25